OrganOx
OrganOx develops and commercializes the metra normothermic machine perfusion platform, the first commercial NMP system for liver transplantation, sold to transplant centers, hospitals, and OPOs across the U.S., U.K., EU, Australia, and Canada. Acquired by Terumo Corporation for $1.5 billion in October 2025.
- Company typePrivate
- Founded2008
- HeadquartersOxford, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What OrganOx does
OrganOx is a UK-headquartered medical technology company that develops and commercializes normothermic machine perfusion (NMP) platforms for organ preservation and assessment. Founded in 2008 as a spin-out from the University of Oxford by Professors Peter Friend and Constantin Coussios, the company built the metra system — the first commercial NMP platform for liver transplantation — which maintains donor livers in a metabolically active, oxygenated, blood-based perfusate at normal body temperature. The metra platform integrates a centrifugal pump, self-regulating oxygenator, soft-shell perfusate reservoir, in-line blood gas analyzer, automated medication infusion driver, and touchscreen interface, and has been used in over 10,000 liver transplants globally. OrganOx holds FDA approval (granted 2021), CE Mark, UKCA, Australian TGA approval, and Health Canada licensure, with additional FDA clearance for air transport and an IND clearance for an investigational Extracorporeal Liver Cross-Circulation (ELC) system co-developed with eGenesis.
The company generates revenue primarily through sales of the metra capital equipment, associated consumables, and service contracts to transplant centers and hospitals, supplemented by training and certification programs for clinical teams. Go-to-market is enterprise field sales direct to transplant centers across the U.S., U.K., EU, Australia, and Canada, augmented by channel partnerships with organ procurement organizations (OPOs) and recovery/logistics providers such as ProCure On-Demand and Strata Critical Medical. The clinical value proposition — backed by the COPE European randomized trial — is up to 50% lower graft injury, up to 50% reduction in organ discard rates, and ~20% increase in transplant volume versus static cold storage.
In October 2025, Terumo Corporation completed a $1.5 billion acquisition of OrganOx, making it a wholly owned subsidiary (also referenced as Terumo Organ Technologies). The deal followed a $160 million private placement in early 2025 and represented one of the largest UK medtech exits. Post-acquisition, OrganOx continues to operate from its Oxford headquarters with a Madison, New Jersey U.S. presence, and appointed Naoya Iwata, formerly Chief of Staff to Terumo's CEO, as CEO & President effective June 1, 2026, reflecting the parent's intent to leverage Terumo's global infrastructure for further commercial and clinical expansion of the platform.
OrganOx firmographics
Firmographics- Name
- OrganOx
- Legal name
- OrganOx Limited
- Website
- https://organox.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- OrganOx develops and commercializes the metra normothermic machine perfusion platform, the first commercial NMP system for liver transplantation, sold to transplant centers, hospitals, and OPOs across the U.S., U.K., EU, Australia, and Canada. Acquired by Terumo Corporation for $1.5 billion in October 2025.
- Ownership category
- akta.pro rank
OrganOx industry classification
Industry- Product category
- Organ Transplantation Medical Devices
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Transplant Hepatology (HLAKAEAK)
- akta.pro secondary industries
- Hepatology & Liver Disease (HLAKAEAB), Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
Keywords
Where OrganOx is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
OrganOx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- metra® Device Sales and Service: OrganOx generates revenue through the sale and service of its metra® normothermic machine perfusion device to transplant centers and hospitals. The device is a capital equipment with associated consumables and support services.
- Training and Certification Services: OrganOx provides education and certification through exclusive training programs for clinical teams using the metra® platform, supporting transplant centers and organ procurement organizations.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
OrganOx product offering
Product offeringCore offering
OrganOx develops, manufactures, and sells the metra normothermic machine perfusion (NMP) platform, the world's first NMP device for liver transplantation. The system keeps donor livers metabolically active outside the body by perfusing them with oxygenated, warmed blood-based perfusate at near-physiological pressures, extending preservation time and enabling functional viability assessment prior to transplant. The company also offers clinical training and certification services for transplant centers, and is developing an investigational Extracorporeal Liver Cross-circulation (ELC) System in partnership with eGenesis for acute-on-chronic liver failure treatment.
Product overview
OrganOx offers a platform-based product portfolio centered on the metra normothermic machine perfusion (NMP) technology. The core product is the OrganOx metra, the world's first NMP platform for liver transplantation, which maintains donor organs in a metabolically active state outside the body. The platform includes supporting applications like metra Assist and mApp. An investigational extension is the Extracorporeal Liver Cross-circulation (ELC) System, co-developed with eGenesis for acute-on-chronic liver failure treatment using genetically engineered porcine livers. The technology has received regulatory approvals in the U.S. (FDA), Europe (CE Mark), UK (UKCA), Australia, and Canada (licensed).
Differentiator
Problem solved
Functional benefit
Brands
- metra: The OrganOx metra is a normothermic machine perfusion (NMP) platform technology for liver transplantation that keeps donor livers metabolically active outside the body, enabling extended preservation and functional assessment prior to transplant.
Products and services
- OrganOx metra The OrganOx metra is a normothermic machine perfusion (NMP) platform for liver transplantation. It keeps donor livers metabolically active outside the body by continuously perfusing them with oxygenated blood-based perfusate, medications, and nutrients at normal body temperature, enabling extended preservation times and functional viability assessment prior to transplant. Sold as capital equipment to hospitals, transplant centers, and organ procurement organizations.
- Extracorporeal Liver Cross-circulation (ELC) System An investigational liver support system combining OrganOx's automated NMP technology with a patient support accessory device. Co-developed with eGenesis to treat patients with acute-on-chronic liver failure using genetically engineered human-compatible porcine livers (EGEN-5784). Currently in Phase 1 clinical trials under FDA IND clearance.
- Training and Certification Services Education, clinical training, and certification programs for clinical teams using the metra platform. OrganOx provides exclusive training to support transplant centers and organ procurement organizations deploying the metra system.
Quantifiable outcome
- 50% lower graft injury vs static cold storage despite 54% longer preservation time
- +3 more outcomes
Companies that use OrganOx
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles2 records
OrganOx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
OrganOx partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Strata Critical MedicalcorePartnership with Strata Critical Medical (NASDAQ:SRTA) for 24/7 device-to-donor support across the U.S., enabling air and ground transportation of donor livers on the metra® device. FDA approval for air transport enables nationwide coverage.
- Terumo CorporationcoreAcquired OrganOx for approximately $1.5 billion, making OrganOx a wholly owned subsidiary. Transaction completed October 30, 2025. Positions OrganOx to leverage Terumo's global infrastructure for expansion.
- ProCure On-DemandcorePartnership to expand access for liver transplants by combining OrganOx's NMP technology with ProCure's advanced surgical, perfusion, preservation, and logistics solutions. OrganOx supports ProCure's clinical teams through education and certification.
- eGenesiscoreExclusive clinical co-development agreement to advance a liver support system combining OrganOx's NMP technology with eGenesis's human-compatible, genetically engineered porcine livers (EGEN-5784) for treatment of patients with acute-on-chronic liver failure. The FDA cleared the IND application in April 2025 for Phase 1 clinical trials.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
OrganOx competitors and assessment
Company assessmentDirect peers
- TransMedics: TransMedics develops the Organ Care System (OCS), a portable ex-vivo perfusion and monitoring system for lung, heart, and liver transplantation. It is the most direct competitor to OrganOx's metra in liver NMP, serving the same transplant centers with a competing clinical evidence base.
- XVIVO Perfusion: XVIVO Perfusion provides machine perfusion technology for organ transplantation, with established leadership in lung perfusion (XPS and LS) and expanding into liver and other organ preservation. Directly comparable to OrganOx as a perfusion technology peer serving transplant centers globally.
- Organ Recovery Systems: Organ Recovery Systems manufactures the LifePort Kidney Transporter, a machine perfusion device for kidney preservation, and has expanded into liver preservation. Directly comparable to OrganOx as a perfusion technology peer for solid organ transplantation, with overlapping transplant center customer base.
- Bridge to Life: Bridge to Life manufactures and distributes cold storage preservation solutions (Belzer UW and Custodiol) used in organ transplantation. Comparable to OrganOx as the dominant provider of static cold storage solutions, which metra directly competes against in the same transplant center market.
- Preservation Solutions: Preservation Solutions develops and manufactures organ preservation solutions and perfusion equipment used in transplantation procedures. Comparable to OrganOx as a supplier of organ preservation technology to transplant centers and OPOs.
- Waters Medical Systems: Waters Medical Systems (now part of the broader transplant ecosystem) provides organ preservation and perfusion technologies for kidney and liver transplantation. Comparable to OrganOx as a perfusion equipment manufacturer serving transplant centers.
Emerging players
- Paragonix Technologies: Paragonix Technologies develops hypothermic organ preservation and transport devices for heart, lung, liver, and kidney transplantation. Comparable to OrganOx as an emerging organ preservation technology peer focused on donor organ transport logistics for transplant centers.
Others
- eGenesis: eGenesis develops human-compatible genetically engineered porcine organs for xenotransplantation and is OrganOx's exclusive clinical co-development partner for the ELC system treating acute-on-chronic liver failure. Comparable as a strategic partner in the xenotransplantation and liver failure treatment space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
OrganOx social profiles
Digital presenceOrganOx compliance and trust
Trust signalCompliance7 records
OrganOx financial estimates
Financial estimateRevenue estimate
Valuation estimate
OrganOx leadership team
Management profileNumber of profiles
Profiles18 records
OrganOx funding detail
Funding detailFunding overview
Funding rounds9 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OrganOx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OrganOx
What does OrganOx do?
OrganOx develops, manufactures, and sells the metra normothermic machine perfusion (NMP) platform, the world's first NMP device for liver transplantation. The system keeps donor livers metabolically active outside the body by perfusing them with oxygenated, warmed blood-based perfusate at near-physiological pressures, extending preservation time and enabling functional viability assessment prior to transplant. The company also offers clinical training and certification services for transplant centers, and is developing an investigational Extracorporeal Liver Cross-circulation (ELC) System in partnership with eGenesis for acute-on-chronic liver failure treatment.
Is OrganOx a public or private company?
OrganOx is a private company. It is classified as corporate owned and is currently acquired.
When was OrganOx founded?
OrganOx was founded in 2008. It employs 101 to 250 people.
Where is OrganOx based?
OrganOx is headquartered in Oxford, United Kingdom, in the Europe region.
How does OrganOx make money?
Two revenue lines are on record. metra® Device Sales and Service is the primary driver. The others are training and Certification Services.
Who are OrganOx's main competitors?
Direct peers on record are TransMedics, XVIVO Perfusion, Organ Recovery Systems, Bridge to Life, Preservation Solutions and Waters Medical Systems. Paragonix Technologies is listed as an emerging player. eGenesis is listed as an others.
Does OrganOx have an API?
No public API is recorded for OrganOx.
What industry is OrganOx in?
OrganOx's product category is Organ Transplantation Medical Devices. Its primary akta.pro industry code is HLAKAEAK, Transplant Hepatology, with a secondary code of HLAKAEAB, Hepatology & Liver Disease. Its SIC code is 3845.